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Targeted intracellular protein degradation in eukary-
otes is largelymediated by the proteasome. Here, we
report the formation of an alternative proteasome
isoform in human cells, previously found only in
budding yeast, that bears an altered subunit arrange-
ment in the outer ring of the proteasome core parti-
cle. These proteasomes result from incorporation of
an additional a4 (PSMA7) subunit in the position nor-
mally occupied by a3 (PSMA4). Assembly of ‘‘a4-a4’’
proteasomes depends on the relative cellular levels
of a4 and a3 and on the proteasome assembly chap-
erone PAC3. The oncogenic tyrosine kinases ABL
and ARG and the tumor suppressor BRCA1 regulate
cellular a4 levels and formation of a4-a4 protea-
somes. Cells primed to assemble a4-a4 protea-
somes exhibit enhanced resistance to toxic metal
ions. Taken together, our results establish the exis-
tence of an alternative mammalian proteasome iso-
form and suggest a potential role in enabling cells
to adapt to environmental stresses.
INTRODUCTION
Efficient and selective degradation of cellular proteins is
essential for protein quality control and maintenance of cellular
homeostasis (Lecker et al., 2006). Impaired protein quality con-
trol and degradation are associated with many human diseases,
including cancer, cardiovascular diseases, and aging-related
pathophysiological conditions such as Alzheimer’s disease and
Parkinson’s disease (Paul, 2008). The ubiquitin-proteasome
pathway mediates the majority of targeted protein degradation
in eukaryotic cells under normal conditions (Goldberg, 2003;
Tomko and Hochstrasser, 2013). In most cases, proteins
destined for degradation are first post-translationally tagged
with a polyubiquitin chain, which then targets them to the 26S
proteasome, a 2.6-MDa proteolytic complex (Tomko and Hoch-
strasser, 2013).
The eukaryotic 26S proteasome consists of a 20S core particle
(CP) harboring the proteolytic active sites and a 19S regulatory
particle (RP) that binds to one or both ends of the CP cylinder
and regulates substrate binding and target protein entry into2962 Cell Reports 14, 2962–2974, March 29, 2016 ª2016 The Authorthe CP (Tomko and Hochstrasser, 2013; Tanaka, 2013). The
CP is composed of four heptameric rings stacked along a central
axis in the order a1–7b1–7b1–7a1–7, with a central catalytic cham-
ber bearing the protease active sites (Groll et al., 1997). In the
canonical CP, the a rings have seven different but related a sub-
units, and the b rings each have seven different b subunits. The
catalytic residues of the proteasome are contributed by the b1,
b2, and b5 subunits.
CP assembly is an ordered process requiring several dedi-
cated proteasome ‘‘assembly chaperones’’ (Le Tallec et al.,
2007; Murata et al., 2009; Ramos et al., 1998; Tomko and Hoch-
strasser, 2013). Individual a subunits are thought to first
assemble into an a ring, which then serves as a template for b
ring assembly, followed by the joining of two half-proteasomes;
however, alternative intermediates involving a-b subunit sub-
complexes may also form (Panfair et al., 2015). The proteasome
assembly chaperone POMP (Ump1 in yeast) is important for b
ring assembly, whereas the heterodimeric chaperones PAC1-
PAC2 (Pba1-Pba2 in yeast) and PAC3-PAC4 (Pba3-Pba4 in
yeast) are involved in the efficient assembly of the a ring.
Although it forms a heterodimer with PAC4, PAC3 has also
been suggested to function as a homodimer (Murata et al., 2009).
In addition to the canonical CP, alterations in CP assembly in
mammalian cells yield specialized proteasomes containing
distinct paralogs of the active-site b subunits (Murata et al.,
2009; Tanaka, 2013). One such specialized proteasome is
the interferon g (IFN-g)-inducible ‘‘immunoproteasome,’’ and
another is the thymus-specific ‘‘thymoproteasome.’’ Immuno-
proteasomes are formed by preferential incorporation of the
IFN-g-inducible b1i, b2i, and b5i subunits in place of the canon-
ical b1, b2, and b5 subunits. These proteasomes are important
for generating peptides for antigen presentation by major histo-
compatibility complex (MHC) class I molecules. Thymoprotea-
somes are specifically expressed in thymic cortical epithelial
cells. They are formed by incorporating the thymus-specific
b5t subunit in place of the b5i subunit in the immunoproteasome
and are important in producing peptides involved in the positive
selection of CD8+ T cells (Murata et al., 2009).
Therefore, subtle variations in proteasome CP composition
yield non-canonical proteasomes with altered substrate selec-
tivity and specialized functions. Although specialized protea-
somes formed by alterations in b ring assembly are now well
documented inmammalian cells, there is no evidence of somatic
mammalian cells with alternative a rings. Mouse male germ cells
have been shown to utilize another version of a4, called a4s.s
These paralogous subunits are 85% identical (94% similar) in
sequence, and the functional differences, if any, between a4s
proteasomes and canonical ones remain unknown (Uechi
et al., 2014).
In the baker’s yeast Saccharomyces cerevisiae (S. cerevisiae),
the proteasome is required for viability, but one subunit, a3
(Pre9), is unique in being the only non-essential CP component
(Emori et al., 1991). Yeast lacking a3 assemble an alternative
‘‘a4-a4’’ proteasome by substituting an additional a4 subunit in
the position normally occupied by a3 (Velichutina et al., 2004).
Furthermore, the proteasome assembly chaperone Pba3-Pba4
was identified as a factor that normally prevents assembly of
alternative a4-a4 proteasomes (Kusmierczyk et al., 2008). Inter-
estingly, yeast cells that form such alternative proteasomes
exhibit a growth advantage when exposed to the heavy metal
cadmium (Kusmierczyk et al., 2008). This suggests that a4-a4
proteasomes might enable yeast cells to adapt to certain
cellular stresses, although such proteasomes have not yet
been observed in wild-type (WT) yeast.
Here we provide evidence for formation of the alternative
a4-a4 proteasome isoform in mammalian cells, establishing its
conservation from yeast to humans. The relative levels of a3
(PSMA4) and a4 (PSMA7) subunits and the level of the PAC3 as-
sembly chaperone are important determinants for the assembly
of such proteasomes in human cells. Notably, assembly of a4-a4
proteasomes is enhanced under conditions found in certain
cancers, such as those with high levels of the ABL tyrosine ki-
nase. Furthermore, mammalian cells primed to assemble these
alternative proteasomes exhibit enhanced resistance to cellular
stress induced by metal ions. Taken together, our work estab-
lishes that the capacity to form alternative a4-a4 proteasomes
is evolutionarily conserved and implicates this proteasomal
isoform in human disease.
RESULTS
Human a4 Can Rescue Growth of Yeast Lacking Both a3
and a4
In our earlier study, we had found that the Arabidopsis thaliana
proteasome subunit a4 (PAD1) can take the place not only of
S. cerevisiae a4 (Pre6) but also a3 (Pre9) (Velichutina et al.,
2004). This is reflected in the ability of the plant PAD1 gene to
rescue the lethal phenotype of both a4D and a3D a4D mutants.
To test the ability of the human a4 (PSMA7) subunit to replace
a4 and a3 in the yeast proteasome,we performedplasmid shuffle
experiments. A plasmid carrying human a4 was transformed into
a4D and a3D a4D strains containing an URA3-marked plasmid
with the WT yeast a4 gene. Eviction of the original a4 plasmid
on plates containing 5-fluoroorotic acid (FOA), which is lethal to
URA3-expressing cells, resulted in viable colonies with both mu-
tants (Figure 1A). This result suggests that, similar to plant PAD1,
human a4 can incorporate into the yeast proteasome and is also
capable of occupying twopositions in theCP, supporting the idea
that this ability is conserved among higher eukaryotes.
The growth of the a4D and a3D a4D mutants expressing
human a4 was then compared with the equivalent strains ex-
pressing yeast a4. We performed serial dilution growth assays
at 30C and 36.5C. The matched strains grew similarly atCell30C, the optimal growth temperature, regardless of the species
source for the a4 subunit, and the same was true when comple-
mentation was tested in the a4D single mutant at the higher
temperature (Figure 1B). In contrast, the a3D a4D yeast mutant
expressing either the yeast or human a4 gene barely grew at
36.5C. The double mutant transformant still lacked a3, so this
result is consistent with previously published data showing tem-
perature-sensitive growth of a3D cells (Velichutina et al., 2004).
To verify that human a4 forms alternative a4-a4 proteasomes
in a3D a4D yeast, we adapted a previously developed disulfide
engineering approach (Velichutina et al., 2004). In our earlier
study, we mutated residues N79 and I155 of yeast a4 to cyste-
ines, which enabled detection of disulfide crosslinks between
neighboring a4 subunits in the alternative proteasome isoform
(Figure 1C). The structures of 20S proteasomes from yeast and
mammals are highly similar (Unno et al., 2002), and alignment
of their a4 sequences suggested that the human a4 residues
T77 and T152 correspond to the residues in yeast a4 that were
efficiently crosslinked when changed to cysteine. These human
a4 residues were therefore also mutated to cysteines by site-
directed mutagenesis.
We first tested whether the engineered double-cysteine muta-
tion in human a4 (a4-Hs-CC) could be used to detect a4-a4 pro-
teasome assembly in yeast. Cell lysates from a3D a4D yeast ex-
pressing either wild-type human a4 (a4-Hs-WT) or the cysteine
substitution mutants were treated with an oxidant (CuCl2) and
analyzed by non-reducing SDS-PAGE and immunoblotting. A
60 kDa band was specifically detected in cells expressing
a4-Hs-CC but not the a4-Hs-WT or single cysteine substitution
mutants (Figure 1D; Figure S1A). The intensity of the crosslinked
species increased in a time-dependent fashion upon treating the
cell lysate with the oxidant. Loss of the 60 kDa species after
treating the sample with the reducing agent DTT was consistent
with this species representing a divalent a4-a4 dimer.
To determine whether the a4 interaction detected by cross-
linking of whole cell lysates reflected the a ring configuration in
fully assembled functional 26S proteasomes rather than dead-
end intermediates, we isolated active 26S proteasomes from hu-
man a4-expressing a3D a4D yeast cells by nondenaturing PAGE
(native PAGE). The active complexes were identified by a sub-
strate overlay assay. The excised complexes were then sub-
jected to non-reducing SDS-PAGE and immunoblotting (as
shown in Figure 1D) to detect the crosslinked a4-a4 species.
Indeed, we saw the 60-kDa crosslinked a4-a4 band specif-
ically in 26S proteasomes from cells expressing a4-CC but not
a4-WT or the single cysteine substitution mutants (Figure 1E;
Figure S1B). No crosslinked a4-a4 dimers were seen in protea-
somes isolated from the a4D single mutant, consistent with the
presence of endogenous a3, which limits a4 incorporation at
the a3 position (Velichutina et al., 2004). In addition to establish-
ing the shared positional plasticity of yeast and human a4
subunits, these results confirmed the utility of the specific engi-
neered cysteine mutations in human a4 as a means to examine
alternative a4-a4 proteasomes.
Human Cells Can Assemble a4-a4 Proteasomes
To determine whether the ability to assemble alternative a4-a4
proteasomes is unique to budding yeast or conserved in otherReports 14, 2962–2974, March 29, 2016 ª2016 The Authors 2963
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Figure 1. Human a4 Can Replace Yeast a4
in Yeast Proteasomes and Form Alternative
a4-a4 Proteasomes in Mammalian Cells
(A) a4-Hs expression in yeast allows growth in cells
lacking Pre6 (a4-Sc) or both Pre6 and Pre9 (a3-Sc).
Eviction of YCplac33-a4-Sc in a4D and a3D a4D
yeast strains carrying either p424-GPD- a4-Hs or
pRS424-a4-Sc results in viable colonies. The empty
vector control showed no growth.
(B) Plate growth assay using serially diluted a4D
(pre6D) and a3D a4D (pre9D pre96D) yeast cells
transformed with either pRS424-PRE6 (a4-Sc) or
p424GPD-PSMA7 (a4-Hs), which express yeast and
human a4, respectively, and spotted on medium
lacking tryptophan in 10-fold serial dilutions.
(C) Schematic illustrating disulfide bond formation
between engineered cysteines in a4 subunits when
twoa4subunits areadjacent toeachother in thea ring.
(D) a4-Hs can form a4-a4 proteasomes in yeast.
a4-Hs-CC (a4 T77C:T152C) subunits were disulfide-
crosslinked under oxidizing conditions (CuCl2) in
lysates, resolved by nonreducing SDS-PAGE, and
immunoblotted with anti-a4. a4 monomer and dimer
bands are indicated by black arrowheads. Additional
uncharacterized oxidation products accumulated in
both samples. Samples marked 4* and 8* were the
same as those in lanes 4 and 8, respectively, but
were treated with a reducing agent (DTT). Also see
Figure S1A. IB, immunoblot.
(E) Crosslinking of neighboring human a4 subunits
can be detected in functional yeast 26S protea-
somes purified (using native gel separation) from
a3D a4D cells expressing a4-Hs-CC. No a4-a4 di-
mers are seen in the a4D single mutant, which still
has endogenous a3 (lane 1), or with WT a4 that lacks
the engineered cysteine residues (lane 2). Also see
Figure S1B.
(F) Ectopic expression of a4-Hs-CC results in
formation of a4-a4 proteasomes in HEK293T cells.
Whole-cell extracts bearing disulfide-crosslinked a4
were analyzed as in (D) with yeast extracts, except
no CuCl2 was added.eukaryotes, we transfected HEK293T cells with either the a4-
Hs-WT or cysteine substitution mutants. Expression of the
a4-CC mutant, but not a4-WT or the single cysteine mutants,
yielded the 60-kDa species corresponding to the disulfide
crosslinked a4-a4 dimer (Figure 1F). Unlike in yeast, the forma-
tion of a4 crosslinks in these cells did not require addition of
external oxidizing agents to the cell lysate, suggesting that
the lysis (or cellular) conditions were already sufficiently
oxidizing to induce disulfide bond formation. Additional oxida-
tion products were also observed, as was the case in yeast,
but these species were not characterized further. We also
tested the ability of multiple human cell types (including the
IMR-90 primary cell line derived from human fetal lung) to
assemble alternative proteasomes (Figure S1C). Our results
demonstrate that the ability to assemble a4-a4 proteasomes
is conserved across transformed and primary human cell lines.
Finally, we found that a4 dimers were also seen in fully assem-
bled 26S proteasomes isolated from human cells and not just
assembly intermediates or dead-end products (Figure S1D;
Figure 2D).2964 Cell Reports 14, 2962–2974, March 29, 2016 ª2016 The AuthorChanges in a3 Levels Modulate a4-a4 Proteasome
Assembly in Human Cells
Inasmuch as deletion of the a3 gene induces assembly of the
alternative a4-a4 proteasome isoform in yeast (Velichutina
et al., 2004), we tested the effect of reducing a3 levels on
a4-a4 proteasome assembly in human cells. We first created
an isogenic Flp-In HeLa cell line stably expressing a4-CC-
FLAG under a doxycycline (Dox)-responsive promoter and then
knocked down a3 levels by 50% with a lentivirus-delivered
short/small hairpin RNA (shRNA) (Figures 2A and 2B). a3 knock-
down enhanced assembly of a4-a4 proteasomes, as indicated
by the increase in the 60 kDa a4-a4 crosslinked species
(Figure 2C). Multiple shRNAs targeting different regions of a3
also resulted in an increase in alternative proteasome assembly
in HeLa cells transiently transfected with a4-CC (Figure 2A; Fig-
ures S2A and S2B).
Similar to the results obtained with HeLa cells, knockdown of
a3 in U2OS cells also resulted in increased a4-a4 levels, indi-
cating a general effect in different cell types (Figure S2C). The in-
crease in a4-a4 crosslinking observed upon a3 knockdowns
AB
C
D
E F G
Figure 2. a3 Regulates a4-a4 Proteasome Assembly in Human Cells
(A) Schematic illustrating regions of the a3 gene targeted by different shRNAs.
(B) shRNA-mediated knockdown (KD) of a3 in stable a4-CC-FLAG (HeLa) cells. The a3-1 shRNA caused an50%decrease in a3 levels. a4-CC-FLAG expression
was induced by the addition of Dox.
(C) a3 knockdown in a4-CC-FLAG stable HeLa cells results in increased assembly of a4-a4 proteasomes. Also see Figure S2.
(D) Confirmation of the increase in a4-a4 proteasomes upon a3 knockdown using gel-isolated HeLa cell 26S proteasomes.
(E) Ectopic overexpression of a3 in a4-overexpressing HeLa cells causes a decrease in a4-a4 proteasome formation based on a4-a4 crosslinking.
(F) a6-FLAG expression was induced in stable a6-FLAG HeLa cells by addition of Dox. a4-WT or a4-CC was transiently expressed in these cells.
(G) The a6 expression level does not affect a4-a4 proteasome assembly. a6-FLAG expression was induced in a6-FLAG stable HeLa cells by addition of Dox
(Figure 2F).using whole cell extracts was also observed in gel-isolated
active 26S proteasomes (Figure 2D). This confirmed that the
difference in abundance of proteasome isoforms detected by
disulfide crosslinking using cell lysates mirrors the changes in
fully assembled proteasomes. Conversely, overexpression of
ectopic a3 resulted in decreased alternative proteasome assem-Cellbly in a4-CC-overexpressing HeLa cells (Figure 2E), consistent
with an inverse relationship between a3 levels and a4-a4 protea-
some formation. No effect on a4-a4 proteasome assembly was
observed upon overexpression of another CP a subunit, a6
(PSMA1), confirming that the effect of a3 on a4-a4 proteasome
assembly was specific (Figures 2F and 2G). Taken together,Reports 14, 2962–2974, March 29, 2016 ª2016 The Authors 2965
these results establish cellular a3 levels as an important deter-
minant in regulating the assembly of this alternative proteasome
isoform in human cells.
PAC3 Levels and Cadmium Regulate a4-a4 Proteasome
Assembly
The heterodimeric CP assembly chaperone Pba3-Pba4 was
identified as an important factor that limits a4-a4 proteasome
formation in yeast (Kusmierczyk et al., 2008). To determine
whether PAC3, the mammalian ortholog of Pba3, influences as-
sembly of this isoform in mammalian cells in a similar way, we
used shRNA to knock down PAC3 in isogenic Flp-In HeLa cells
stably expressing a4-CC-FLAG (Figures 3A and 3B). Knockdown
of PAC3 enhanced a4-a4 proteasome assembly (Figure 3C).
This result was further verified using two different shRNAs
against PAC3, both of which caused an increase in a4-a4 protea-
some assembly in HeLa cells transiently transfected with a4-CC
(Figure 3A; Figures S3A andS3B). By contrast, overexpression of
ectopic PAC3 in cells stably expressing a4-CC-FLAG strongly
decreased a4-a4 proteasome assembly (Figures 3D and 3E).
Therefore, as in yeast, PAC3 (presumably as part of the PAC3-
PAC4 dimer) is an important regulator of a4-a4 proteasome
assembly in human cells.
During our efforts to identify conditions that might affect a4-a4
proteasome assembly, we found that exposure to the heavy
metal cadmium caused an 50% decrease in cellular PAC3
levels (Figure 3F). Most or all of the effect of CdCl2 on PAC3 pro-
tein levels appeared to be through reduction of PAC3 mRNA
(Figure 3G). Because PAC3 plays an important role in regulating
the assembly of a4-a4 proteasomes, we tested the effect of
CdCl2 on a4-a4 proteasome levels. As shown in Figure 3H and
Figure S3C, CdCl2 treatment led to an increase in a4-a4 protea-
some assembly in both HeLa and HEK293T cells. CdCl2 is
known to induce an oxidizing cellular environment, which could
potentially have caused an increase in in vivo disulfide crosslink-
ing (Nemmiche et al., 2011). Therefore, we wanted to establish
whether the observed increase in a4-a4 crosslinking reflects
an actual increase in a4-a4 proteasomes in response to reduced
PAC3 levels or is an artifact of altered cellular oxidative condi-
tions. Because short-term treatment of cells with CdCl2 is suffi-
cient to alter cellular redox but not enough to decrease PAC3
levels, we analyzed a4-a4 crosslinking in cells subjected to
CdCl2 treatment for 3 or 24 hr (Figure S3D; Nair et al., 2013).
Unlike the 24-hr treatment, short-term exposure to CdCl2 had
no effect on a4-a4 dimer levels, suggesting that reduced
PAC3, rather than enhanced disulfide bond induction, is likely
to mediate the CdCl2-induced assembly of the a4-a4 protea-
some variant (Figure S3E).
a4 Overexpression Rescues the Viability of a3
Knockdown Cells
Unlike in yeast, where a3 deletion is well tolerated under normal
growth conditions, potent a3 knockdown caused strong pheno-
typic abnormalities and a decrease in cell viability in human
cells. Cultured human cells with reduced a3 levels formed long
branched structures resembling neuron-like projections (Fig-
ure 4A). This change in cell morphology was absent in the
corresponding GFP knockdown control cells. The a3 knock-2966 Cell Reports 14, 2962–2974, March 29, 2016 ª2016 The Authordown-induced changes in morphology were consistently
observed using multiple shRNAs targeting different regions of
a3 (data not shown). Furthermore, prolonged a3 knockdown re-
sulted in decreased cell viability, suggesting that mammalian
cells are more dependent on a3 for cell survival than yeast. All
protein analyses shown in this study were performed before
any decrease in cell viability was observed.
To confirm that the decrease in viability of cells treated with a3
shRNA was not an off-target effect of the shRNA, we tested the
ability of ectopic shRNA-resistant a3 to rescue the decreased
viability. For this, we generated a Dox-inducible stable HeLa
cell line expressing a3 with silent mutations that protected it
from the shRNA against a3 (Figure S4A). The expression of
shRNA-resistant a3 protected the cells from a3 knockdown-
induced cell death. In contrast, cells overexpressing WT
(shRNA-sensitive) a3 failed to rescue growth, indicating that it
is the decrease in a3 levels that reduced cell viability (Figure 4B;
Figures S4B and S4C).
The results shown in Figures 4A and 4B suggest that endoge-
nous a4 is either incapable of overcoming the loss of a3 through
a4-a4 proteasome assembly or is expressed at insufficient
levels to allow rescue. If the latter explanation is correct, then
overexpression of a4 in a3 knockdown cells should enhance as-
sembly of a4-a4 proteasomes and rescue the decreased viability
of these cells. Indeed, a4 overexpression in cells resulted in
increased tolerance of a3 knockdown (Figure 4C; Figures S4D
and S4E). Overexpression of another proteasome a subunit,
a6, had no effect on either a4-a4 proteasome formation or a3
knockdown-induced cell death (Figures S4F and S4G).
Oncogenic ABL and ARG Kinases and the Tumor
Suppressor BRCA1 Have Reciprocal Effects on the
Assembly of a4-a4 Proteasomes
Increasing cellular levels of a4 caused corresponding increases
in a4-a4 proteasome assembly (Figure 4D). Interestingly, the
related cytoplasmic tyrosine kinases ABL and ARGwere recently
reported to reduce degradation of a4 protein and thereby pro-
mote its accumulation (Li et al., 2015). This was accompanied
by an increase in total proteasome levels and proteolytic capac-
ity of the cells (Li et al., 2015; Figure S5B). We hypothesized that
the enhanced proteasome levels and activity observed in cells
overexpressing these oncogenic kinases result, at least in part,
from increased assembly of a4-a4 proteasomes. To determine
whether ABL and ARG overexpression causes such an increase,
a4-CC-FLAG was co-expressed along with either ABL or ARG in
HEK293T cells. Concomitant expression of ABL or ARG kinase
along with a4-CC-FLAG resulted in increased levels of a4
and a4-a4 proteasomes (Figures 4E and 4F). This increased as-
sembly of a4-a4 proteasomes in the presence of ABL or ARG
required their kinase activity because the effect was suppressed
by addition of the ABL/ARG kinase inhibitor STI571 (imatinib)
(Figure 4G). We noted that overexpression of ABL and ARG
had no effect on PAC3 levels in HEK293T cells (Figure S4H).
The tumor suppressor proteinBRCA1waspreviously identified
asaubiquitin ligase that targets freea4 for proteasome-mediated
degradation (Li et al., 2015). Correspondingly, we found that co-
expression of BRCA1 with a4-CC-FLAG in HEK293T cells re-
sulted in decreased levels of a4-a4 proteasomes (Figure 4H).s
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Figure 3. The Proteasome Assembly Chaperone PAC3 Regulates a4-a4 Proteasome Assembly in Human Cells
(A) Schematic illustrating different PAC3 gene regions targeted by PAC3 shRNAs.
(B) shRNA-mediated knockdown of PAC3 in a4-CC-FLAG stable HeLa cells using PAC3-1 shRNA.
(C) PAC3 knockdown results in increased a4-a4 proteasome assembly in stable a4-CC-FLAG-expressing cells. Also see Figure S3.
(D) Ectopic overexpression of PAC3 does not affect a4 levels.
(E) Overexpression of PAC3 reduces a4-a4 proteasome assembly in Dox-induced a4-CC-FLAG cells.
(F) Treatment of HeLa cells with 10 mM CdCl2 for 24 hr results in an 50% decrease in PAC3 levels.
(G) CdCl2 causes a decrease in PAC3 mRNA levels. The results represent three independent experiments in which mRNA levels were measures by qRT-PCR.
**p < 0.05 (Student’s t test).
(H) CdCl2 treatment (10 mM) leads to enhanced a4-a4 proteasome assembly in a4-CC-Flag stable HeLa cells. a4-CC-Flag expression was induced in a4-CC-Flag
stable HeLa cells by addition of Dox.
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These results suggest that the unique regulation of a4 levels by
the ABL and ARG kinases and the BRCA1 ubiquitin ligase also
leads to changes in levels of the a4-a4 proteasome isoform.
Increased ABL kinase activity resulting from chromosomal
translocation of ABL to the BCR locus has a causal role in
chronic myelogenous leukemia (CML) (Ren, 2005). Amplification
of the genomic locus harboring a4 (PSMA7) (20q13) has been re-
ported in several cases of cervical and colon cancer (Hu et al.,
2008; Scotto et al., 2008). Consistently, higher a4 protein levels
have been detected in 38.8% of colorectal cancer primary sites
(24 of 62), 52.9%of lymph nodemetastases (18 of 34), and 100%
of liver metastases (13 of 13) (Hu et al., 2008). Furthermore,
genome-wide gene expression studies have shown that a4
mRNA levels are elevated in testicular and breast cancer (Fig-
ure S4I; Korkola et al., 2006; Richardson et al., 2006). Increased
a4 expression is also observed in castration-recurrent prostate
cancer (Romanuik et al., 2010). These data, taken together, sug-
gest that a4 levels are selectively upregulated in various cancers
through multiple mechanisms. Our results show that this can
lead to increased assembly of a4-a4 proteasomes, which may
have a role in promoting these malignancies.
Assembly of a4-a4 Proteasomes Correlates with
Enhanced Heavy Metal Resistance
Because elevated a4 levels are observed in several cancers, we
sought to clarify the effect of increased a4 levels on the proteo-
lytic capacity of cells (Hu et al., 2008; Romanuik et al., 2010).
Overexpression of a4-FLAG resulted in increased levels of
cellular proteasome activity (Figures 5A and 5B), as observed
previously (Li et al., 2015). Overexpression of a4 also resulted
in increased levels of 26S and 20S proteasomes (Figure 5C; Fig-
ure S5A). As expected, overexpression of ABL or ARG concom-
itantly with ectopic a4 appeared to further enhance proteasome
activity, as determined by in-gel assays (Figure S5B). To evaluate
whether this increased proteolytic capacity translates into higher
resistance to proteotoxic stresses, we challenged cells express-
ing high levels of a4 with increasing concentrations of the toxic
metal ions cadmium or copper. These chemicals have the poten-
tial to alter cellular redox states and cause oxidative protein
damage, which increases the load on cellular proteasomes
(Pourahmad andO’Brien, 2000). Cells expressing elevated levels
of a4were primed to assemble a4-a4 proteasomes, and they ex-
hibited significantly higher resistance to the toxicity induced by
CdCl2 and CuCl2 (Figures 5D and 5E; Figure S5C). In contrast
to a4 overexpression, ectopic expression of a6 had little or no ef-
fect on the ability of cells to resist metal-induced toxicity (Figures
5F and 5G; Figure S5D). Taken together, these results demon-
strate that multiple mechanisms leading to increases in a4 levels
cause elevated levels of active proteasomes. Because our data
also indicate that high a4 levels increase assembly of the a4-a4
proteasome isoform (Figure 4D), it is possible that this variant
helps cells overcome proteotoxic stresses such as those when
cells are exposed to heavy metals (Figure 5D).
The enhanced resistance to heavy metals observed in a4-
overexpressing cells could, in principle, be due to the resulting
higher overall proteasome levels (Figure 5), to the increased
assembly of the a4-a4 proteasome isoform (Figure 4D), or a
combination of these effects. It is noteworthy that yeast cells2968 Cell Reports 14, 2962–2974, March 29, 2016 ª2016 The Authorexpressing a4-a4 proteasomes also display greater cadmium
resistance even though they assemble fewer proteasomes over-
all (Kusmierczyk et al., 2008). Knockdown of either a3 or PAC3 in
human cells also lowered both proteasome activity and levels
(Figures S5E–S5G). At the same time, as shown above, reduction
of cellular a3 and PAC3 promoted the assembly of a4-a4 protea-
somes (Figures 2 and 3). Interestingly, we observed that a mod-
erate reduction of a3 (using a3-1 shRNA) resulted in enhanced
resistance to cadmium (Figure 5H; Figure S5E), whereas a
more drastic reduction of a3 levels (a3-2 shRNA) failed to provide
a survival advantage to the cells when challenged with CdCl2
(Figures S5E and S5H). This suggests that, although enhanced
a4-a4 proteasome assembly might enable the cells to resist
cadmium-induced proteotoxic stress, a reduction in total protea-
some levels below a certain threshold reverses this advantage.
PAC3 knockdown also resulted in modestly enhanced resis-
tance to cadmium toxicity (Figure 5I; Figure S5F). It is possible
that knockdown of a3 and PAC3 also leads to upregulation of
oxidative stress response genes, which can potentially help cells
resist cadmium-induced stress. Interestingly, a6 overexpression
also caused an increase in proteasome levels and activity (Fig-
ures S5I–S5K), but, unlike a4 overexpression, had no effect on
cellular resistance to cadmium or copper, again suggesting
that the ability of cells to assemble an alternative form of the pro-
teasome, rather than just changing its levels, is important in
cellular resistance to heavy metal-induced proteotoxic stress
(Figures 5F and 5G).
DISCUSSION
The Capacity to Assemble a4-a4 Proteasomes Is
Conserved from Yeast to Humans
In this work, we present evidence that human cells can alter pro-
teasome a ring assembly to generate an alternative proteasome
isoform that, our data predict, will accumulate in a variety of
tumors. The a4-a4 proteasome is formed by incorporation of
an additional a4 subunit in the position usually occupied by a3
in either one or both a rings of the CP. Such a4-a4 proteasomes
were previously identified only in certain yeast mutants (Velichu-
tina et al., 2004; Kusmierczyk et al., 2008). Our results establish
that the capacity to form this alternative isoform is evolutionarily
conserved and can occur in non-mutant primary human cell
lines.
The human a4 (PSMA7) gene can successfully complement
not only yeast lacking endogenous a4 (Pre6) but also those
that lack both a3 (Pre9) and a4. The human a4 protein therefore
allows the formation of yeast-human hybrid a4-a4 proteasomes
with four of 28 positions occupied by the human subunit. Human
a4 is 59% identical in sequence to yeast a4 and only 37% iden-
tical to yeast a3. It is therefore remarkable that these cross-
species subunit substitutions are so well tolerated.
In our disulfide crosslinking experiments with mammalian
cells expressing ectopic a4-CC, the sensitivity of the assay is
expected to be reduced because of competition between the
ectopically introduced a4-CCprotein and endogenous a4, which
lacks the engineered cysteines necessary for a4-a4 crosslinking.
Because disulfide crosslinking requires two a4-CC subunits
to be present adjacent to each other in the a ring, the level ofs
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Figure 4. ABL, ARG, and BRCA1 Regulate a4 Levels and a4-a4 Proteasome Assembly, and Elevated a4 Levels Rescue a3 Knockdown-
Induced Loss of Cell Viability
(A) a3 knockdown results in changes in cell morphology. a3 shRNA induces formation of neuron-like cell protrusions in HeLa, U2OS, and IMR-90 cells.
(B) a3 shRNA-induced loss of cell viability is rescued by ectopic expression of shRNA-resistant a3. Flp-In HeLa cells containing stably integrated a3-FLAG with
silent mutations that make it resistant to a3-3 shRNA (a3-rescue cells) were treatedwith either a3-3 shRNA or control GFP shRNA for 4 days. a3-FLAG expression
was induced in these cells by Dox at the same time as shRNA treatment. Cell viability was measured on day 4 using the CellTiter-Glo luminescent cell viability
assay. Data from three experiments were quantified. Error bars represent SD. Also see Figure S4A.
(legend continued on next page)
Cell Reports 14, 2962–2974, March 29, 2016 ª2016 The Authors 2969
a4-a4 proteasomes we observed is likely to be an underestimate
of the total amount of this proteasomal isoform in these cells.
Nevertheless, the assay is sufficiently robust to see changes in
the assembly of alternative a4-a4 proteasomes in cells with
different relative levels of the a3 and a4 subunits or altered
amounts of the CP assembly chaperone PAC3 (Figures 2, 3, 4,
and 6). These observations are very similar to what has been
seen in yeast cells (Velichutina et al., 2004), suggesting a similar
mechanistic basis for their assembly in yeast and humans.
a3 Knockdown Induces Morphologic Changes and Cell
Death in Human Cells
Although several factors important in a4-a4 proteasome assem-
bly are conserved between yeast and humans, some key differ-
ences exist. Most obviously, loss of the CP a3 subunit is not
lethal to S. cerevisiae but is in all the human cell lines we tested,
including primary cells. Despite reduced proteasome assembly
efficiency, a3D yeast cells can still form sufficient levels of the
alternative a4-a4 proteasome to maintain viability (Velichutina
et al., 2004). In contrast, knockdown of a3 in human cells results
in striking morphological changes and, ultimately, loss of cell
viability (Figure 4). Unlike in yeast, the endogenous levels of a4
in mammalian cells fail to overcome a3 loss in the cell lines we
tested. Ectopic expression of a4, however, substantially sup-
presses the defects caused by reduced a3 levels (Figure 4C).
This result supports the idea that, under physiological conditions
that increase cellular a4 levels, mammalian cells can also
accommodate a reduction in a3 by assembling a4-a4 protea-
somes. This might promote cell survival under specific condi-
tions or in certain cancers.
a3 knockdown results in cells becoming less rounded and
developing long, thin protrusions. Because this morphology re-
sembles that of senescent cells, we stained a3 knockdown
and control cells for b-galactosidase activity, a known marker
for senescence. b-Galactosidase staining was similar under
the two conditions, suggesting that the a3-deficient cells are
not senescent (data not shown). The cause of the altered
morphology remains to be determined.
Potential Role of Alternative a4-a4 Proteasomes in
Human Disease
Amplification of the genomic locus 20q13, which harbors a4
(PSMA7), has been reported in several cases of colon and cervi-
cal cancer, and a4 protein levels have also been shown to be
elevated at both primary colon cancer and metastatic sites (Hu
et al., 2008; Scotto et al., 2008). Moreover, analysis of published(C) Ectopic expression of a4 also rescues a3 shRNA-induced loss of cell viability.
a3-2 shRNA or control GFP shRNA for 8 days. a4-FLAG expression was induced
measured on day 8 as in Figure 3B. Data from three experiments were quantified
(D) Top: the level of a4-a4 proteasomes in cells correlates with the level of a4
corresponding increases in a4-a4 proteasomes. Bottom: total a4 protein levels i
(E) Transient overexpression of ABL-63His and ARG-EYFP in HEK293T cells resul
FLAG.
(F) Expression of ABL or ARG tyrosine kinase in HEK293T cells expressing a4-C
(G) Increased formation of a4-a4 proteasomes upon ABL and ARG overexpress
co-expressing a4-CC-FLAG and either ABL or ARG with the inhibitor STI571 (im
(H) Overexpression of BRCA1 (bottom) causes a decrease in a4-a4 proteasome
2970 Cell Reports 14, 2962–2974, March 29, 2016 ª2016 The Authorgene expression data reveals selective upregulation of a4mRNA
in multiple cases of testicular and breast cancer (Figure S4I; Kor-
kola et al., 2006; Richardson et al., 2006). A significant reduction
in a3 expression is simultaneously observed in two of the testic-
ular cancer datasets (mixed germ cell tumor and embryonal
carcinoma), which should further enhance a4-a4 proteasome
formation. On the other hand, both a3 and a6 levels remained
unchanged in the breast cancer dataset (data not shown;
Figure S4I; Korkola et al., 2006; Richardson et al., 2006). a4
expression was also found to be elevated in castration-recurrent
prostate cancer (Romanuik et al., 2010). These data highlight po-
tential physiological scenarios during carcinogenesis where
increased endogenous a4 levels, particularly when a3 levels
are simultaneously reduced, would likely result in enhanced
a4-a4 proteasome assembly, which might contribute to the de-
regulated growth of cancer cells (Figure 6).
The a4-a4 proteasome has properties that are distinct from
those of the canonical CP (Emori et al., 1991; Velichutina et al.,
2004). The absence of a3 in the a ring eliminates the closed-
gate conformation, which normally prevents substrate entry
through the central pore (Osmulski et al., 2009). This leads to
higher basal peptidase activity of the a4-a4 CP variant. The
change in the a ring alters the interface with the RP and other
CP regulators, such as PA28 and PA200, potentially changing
the regulation of CP activity (Stadtmueller and Hill, 2011).
When a4-a4 proteasomes form in yeast, changes in RP assem-
bly are also observed (Kusmierczyk et al., 2008). Finally, yeast
cells that only contain the a4-a4 proteasome isoform have selec-
tive defects in the degradation of ubiquitin-proteasome system
substrates (Velichutina et al., 2004). This may be due to the
reduced assembly efficiency of the alternative isoform relative
to the canonical CP or to one or more of the aforementioned
changes.
The oncogenic tyrosine kinases ABL and ARG phosphorylate
a4, which stabilizes the free subunit and increases its levels in
cells (Li et al., 2015). We show that ABL or ARG overexpression
also increases a4-a4 proteasome assembly (Figure 4F) and
cellular proteolytic capacity (Figure S5B; Li et al., 2015). ABL/
ARG overexpression causes an increase in total cellular protea-
some levels (Li et al., 2015). We hypothesize that the increased
proteasome levels upon ABL and ARG overexpression are at
least partly accounted for by the additional a4-a4 proteasomes
induced by elevated cellular a4 (Figure 6). ABL activity is upregu-
lated in certain cancers, especially CML, where the translocation
of ABL to the BCR locus causes high expression of a constitu-
tively active BCR-ABL fusion protein (Ren, 2005). ElevatedFlp-In HeLa cells containing stably integrated a4-FLAG were treated with either
in these cells by Dox at the same time as shRNA treatment. Cell viability was
. Error bars represent SD. Also see Figure S4D.
. Transfection of increasing amounts of a4-CC in HEK293T cells resulted in
n cell lysates used for the a4-a4 crosslinking assay (top).
ts in a concomitant increase in both endogenous a4 and co-transfected a4-CC-
C-FLAG increases a4-a4 proteasome levels.
ion is dependent on their tyrosine kinase activity. Treatment of HEK293T cells
atinib) decreases a4-a4 levels.
s in HEK293T cells (top).
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Figure 5. High a4 Levels Correlate with Elevated Proteasome Activity and Enhanced Resistance to Toxic Metals
(A) Ectopic expression of a4 (bottom) results in higher 26S and 20S proteolytic activity (top). Cell lysates were resolved by native PAGE, and proteasome activity
was measured by an in-gel substrate overlay assay using the fluorogenic peptide Suc-LLVY-AMC.
(B) a4 overexpression results in an 15% increase in the proteolytic capacity of cells. An in vitro proteasome activity assay was performed on the whole-cell
extract using the fluorogenic peptide substrate Suc-LLVY-AMC. Fluorescence was measured at Ex380nm/Em460nm. The relative fluorescence intensity was
calculated from the mean ± SE of three independent experiments. **p < 0.05 (Student’s t test).
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Figure 6. Model Summarizing the Factors Regulating Assembly of
the Alternative a4-a4 Proteasome Isoform in Human Cells and Their
Potential Physiological Relevance
See main text for details.proteasome activity has also been reported in these cancer cells.
This is consistent with data from Li et al. (2015) and data in this
report showing a direct correlation between the increased ABL
activity and cellular proteasomal proteolytic capacity (Crawford
et al., 2009).
Phosphorylation of a4 at Tyr106 by ABL/ARG protects a4
from BRCA1-mediated ubiquitylation at Lys116 (Li et al., 2015).
Ubiquitylation of a4 by BRCA1 targets it to the proteasome for
degradation (Li et al., 2015). BRCA1 is a known tumor suppres-
sor, and inactivating mutations in BRCA1 are observed in breast
and ovarian cancers (Welcsh and King, 2001). We found that
ectopic BRCA1 expression decreases alternative proteasome
formation (Figure 4H). Taken together, these results suggest a
potential role for a4-a4 proteasomes in the progression of certain
cancers. Given the importance of ABL and ARG kinases in
neuronal development, it will also be interesting to explore po-
tential roles of a4-a4 proteasomes in developing neurons and
in the pathology of neurodegenerative diseases (Koleske et al.,
1998; Schlatterer et al., 2011).
The ability to assemble a4-a4 proteasomes provides mamma-
lian cells a mechanism to alter their proteolytic capacity and
specificity in response to cellular stress. Cells with elevated
levels of a4 are primed to assemble a4-a4 proteasomes and
exhibit greater tolerance for CdCl2 and CuCl2 toxicity (Figure 5).
CdCl2 and CuCl2 can cause oxidative protein damage, resulting
in an increased load on cellular protein degradation pathways.
Higher cellular proteolytic capacity or shifts in the specificity of
proteasomes engendered by the a3-to-a4 subunit swap (or
both) could help these cells overcome the increased load on
the proteasome because of exposure to toxic heavy metals
(Nemmiche et al., 2011; Pourahmad and O’Brien, 2000).(C) Native PAGE-western blot analysis of HEK293T cell lysate reveals increas
Figure S5A.
(D) Dox-induced expression of stably integrated a4-FLAG in Flp-In HeLa cells e
measured using the CellTiter-Glo luminescent cell viability assay. n = 3, and erro
(E) Dox-induced expression of stably integrated a4-FLAG in Flp-In HeLa cells enh
error bars represent SD. Also see Figure S5C.
(F and G) Dox-induced a6 overexpression in a6-FLAG stable HeLa cells had no ef
Cell viability was measured as in Figure 5E. n = 3, and error bars represent SD. A
(H) a3 knockdown in HeLa cells using a3-1 shRNA enhances cadmium (CdCl2)
represent SD. Also see Figure S5E.
(I) PAC3 knockdown in HeLa cells using PAC3-1 shRNA results in slightly enhance
PAC3 in HeLa cells was carried out for 8 days. Cells were treated with 5 mMCdCl2
viability assay. n = 3, and error bars represent SD. **p < 0.05 (Student’s t test). A
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in tumor cells, and tumor cells have a higher demand for protein
turnover to support their rapid proliferation (Balch et al., 2008;
Liou and Storz, 2010). Consistent with this, enhanced protea-
some levels and activity are often observed in cancers, and
several cancer types have been shown to be highly sensitive to
proteasome inhibition (Buac et al., 2013).
The proteasome inhibitors bortezomib and carfilzomib are
used in the treatment of hematological malignancies such as
multiple myeloma and mantle cell lymphoma (Buac et al.,
2013). However, a growing concern with these active site-tar-
geted inhibitors is the emergence of drug resistance (L€u and
Wang, 2013). The need to counter emerging resistance to such
inhibitors makes it important to develop alternative strategies
for reducing proteasome activity or assembly. The selective
increase in a4 in certain cancers suggests a potential role for
a4-a4 proteasomes in sustaining the rapid proliferation of cells
in these malignancies. Therefore, strategies that would enable
us to interfere specifically with the assembly of a4-a4 protea-
somes could have therapeutic potential in tumors where its func-
tion is relevant. This approach might also have fewer side effects
and reduced toxicity compared with existing drugs that target
total proteasome function across all cells. The development of
such strategies will require confirmation of the role of a4-a4 pro-
teasomes in cancer cell proliferation and an in-depth under-
standing of their assembly and function.
EXPERIMENTAL PROCEDURES
Reagents and Strains
Escherichia coli strain TOP10 F’ was used for DNA cloning. The yeast strains
used in this study are listed in Table S1. The shRNA constructs used in this
study are listed in Table S2. The plasmids used in this study are listed in Table
S3. The antibodies used are listed in Table S4.
Mammalian Cell Culture
Mammalian cell lines (HEK293T, HeLa, U2OS, and IMR-90) were grown using
standard cell culture techniques in DMEM supplemented with 10% fetal
bovine serum. IMR-90 cells were purchased from the ATCC. HEK293T,
HeLa, and U2OS cells were obtained as a gift from Christian Schlieker (Yale
University). Low-passage HEK293T cells were used as the packaging cell
line for lentivirus production. See the Supplemental Experimental Procedures
for details regarding the generation of isogenic Flp-In HeLa stable cell lines.
Disulfide Crosslinking Assay to Detect a4-a4 Proteasomes
Yeast cells grown to mid-log phase were harvested, spheroblasted, and
lysed by vortexing. Disulfide crosslinking assays in yeast were performed ase in 26S and 20S proteasome levels upon ectopic a4 expression. Also see
nables the cells to resist exposure to the toxic metal CdCl2. Cell viability was
r bars represent SD. Also see Figure S5C.
ances CuCl2 resistance. Cell viability was measured as in Figure 4C. n = 3, and
fect on the ability of the cells to resist toxicity because of CdCl2 (F) or CuCl2 (G).
lso see Figure S5D.
resistance. Cell viability was measured as in Figure 5E. n = 3, and error bars
d ability of HeLa cells to resist CdCl2 toxicity. shRNA-mediated knockdown of
for 24 hr prior to measuring cell viability using the CellTiter-Glo luminescent cell
lso see Figure S5F.
s
described previously (Kusmierczyk et al., 2008). Human cells were lysed in
lysis buffer (50 mM Tris-HCl [pH 7.5], 75 mM NaCl, 0.5% NP-40, and 5 mM
MgCl2) on ice for 1–1.5 hr prior to crosslinking. See the Supplemental Experi-
mental Procedures for details.
Cell Viability Assay
5,000 cells were plated in each well of a 96-well plate. Cells were treated with
different concentrations of CdCl2 and CuCl2 in triplicate for 24 hr. The number
of viable cells was quantified using the CellTiter-Glo luminescent cell viability
assay (Promega) according to the manufacturer’s instructions. The effect of
a3 shRNA on cell viability was determined 48 hr after plating the cells. The
values reported are the mean ± SD of multiple independent experiments.
In-Gel Substrate Overlay Proteasome Activity Assay
The substrate overlay assay was performed as described previously (Hoch-
strasser and Funakoshi, 2012). To visualize the peptidase activity of intact
26S proteasomes, cell lysates were resolved by native PAGE. The gel was
incubated in developing buffer (50 mM Tris-HCl [pH 7.5], 1 mM ATP, 5 mM
MgCl2, and 10% glycerol) along with 0.1 mM of the fluorogenic substrate
N-succinyl-Leu-Leu-Val-Tyr-AMC (Suc-LLVY-AMC, Sigma) for 30 min at
30C (yeast) or 37C (mammalian cells). Fluorescence (proteasome activity)
was visualized by exposing the gel to UV light on a UV transilluminator.
In Vitro Proteasome Activity Assay
To perform proteasome activity assays in crude lysates frommammalian cells,
the cells were harvested and resuspended in lysis buffer (50 mM HEPES [pH
7.8], 10 mMNaCl, 1.5 mMMgCl2, 1 mM EDTA, 1 mM EGTA, 250 mM sucrose,
and 5 mM EDTA). Cell lysis was achieved by sonicating twice for 10 s (microtip
setting, 2). The protein concentration of the supernatant was determined by
Bradford assay (Bio-Rad protein assay kit). 50 mg protein was used per reac-
tion in a 96-well plate. Reaction buffer (lysis buffer + 2 mM ATP) containing
0.1 mM Suc-LLVY-AMC was added to a final volume of 200 ml. Fluorescence
was measured using a plate reader (SynergyMX, BioTek Instruments) at exci-
tation (Ex)380 nm/emission (Em)460 nm. The relative fluorescence intensity was
calculated from the mean ± SE of three independent experiments.
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